Arbutus Biopharma (LTS:0SGC) Short-Term Capital Lease Obligation : $0.56 Mil (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Arbutus Biopharma Short-Term Capital Lease Obligation?

Arbutus Biopharma's Short-Term Capital Lease Obligation for the quarter that ended in Mar. 2025 was $0.56 Mil.

Arbutus Biopharma's quarterly Short-Term Capital Lease Obligation increased from Sep. 2024 ($0.47 Mil) to Dec. 2024 ($0.48 Mil) and increased from Dec. 2024 ($0.48 Mil) to Mar. 2025 ($0.56 Mil).

Arbutus Biopharma's annual Short-Term Capital Lease Obligation increased from Dec. 2022 ($0.37 Mil) to Dec. 2023 ($0.43 Mil) and increased from Dec. 2023 ($0.43 Mil) to Dec. 2024 ($0.48 Mil).

Arbutus Biopharma Short-Term Capital Lease Obligation Historical Data

The historical data trend for Arbutus Biopharma's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arbutus Biopharma Short-Term Capital Lease Obligation Chart

Arbutus Biopharma Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.39

0.38

0.37

0.43

0.48

Arbutus Biopharma Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial															0.50	0.45	0.47	0.48	0.56

Arbutus Biopharma Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Arbutus Biopharma Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Arbutus Biopharma's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Arbutus Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arbutus Biopharma Corp (LTS:0SGC) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

ABUS:USA I9DN:Germany

Address

701 Veterans Circle, Warminster, PA, USA, 18974

Website

http://www.arbutusbio.com

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Arbutus Biopharma Headlines

No Headlines